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We tested whether methylation profiles generated by real-time
methylation-specific PCR (MSP) can be useful in differentiating
benign, reactive mesothelial cell proliferation (RM) from malig-
nant mesothelioma (MM). Forty-two of the 63 cases (67%)
yielded informative results for RARb2, GPC3, CDKN2A (p16),
TERT, and CCND2 (cyclinD2) gene methylation. DNA methyla-
tion of any gene was observed in much higher frequency in MM
cases than RM cases (63% vs. 33%, P < 0.05). Individual gene
methylation was higher in the MM than the RM cases for most
of the genes; however, this was not statistically significant
(RARb2: 58% vs. 33%, P > 0.05; GPC3: 36% vs. 27%, P >
0.05; CDKN2A: 4% vs. 0%; TERT: 4% vs. 0%), while CCND2
methylation was not detected in any case. Although preliminary,
we demonstrate that real-time MSP can be applied to archival
specimens and gene methylation profiling may have potential to
be a useful ancillary tool to help distinguish MM from RM.
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It is often difficult to differentiate malignant mesothe-
lioma (MM) from reactive mesothelial cell proliferation
(RM) in cytological specimens. Ancillary techniques,
including immunohistochemical staining, have failed to
completely eliminate diagnostic uncertainty. Methylation
of tumor suppressor genes has been shown to be critical
in cancer development, and methylation profiling has
shown potential for clinical utility.1,2 Mesotheliomas, like
other malignancies, have been demonstrated to have a
number of genes methylated, including RASSF1A and
CDKN2A (p16).3,4 In one study, RASSF1A was found
methylated in 32% mesotheliomas,4 and its methylation
was correlated with loss of RASSF1A expression and the
presence of SV40 DNA.4,5 CDKN2A gene alterations are
relatively common in MM, most often inactivated by
homozygous deletion and less common by point muta-
tion.3 Inactivation of CDKN2A gene product expression
by DNA methylation has also been found.3 Another gene
that has been found to be methylated in MM is TERT.
The protein product of TERT gene is the catalytic subunit
of telomerase, which is involved in maintaining telomere
length. Surprisingly, the activation of TERT is related to
DNA methylation of the promoter region, in contrast to
most known tumor suppressor genes’ down-regulation by
DNA promoter methylation.6–8 Reports regarding TERT
activation and MM development have been mixed.9,10 In
contrast, in ovarian and cervical cancer, TERT methyla-
tion increases with age and is associated with a poor
prognosis, regardless of TERT expression.11 DNA
sequence analysis of the TERT promoter region (500 to
þ1, relative to ATG translational site) correlated DNA
methylation with TERT expression among tumors and
TERT positive cell lines.7 Glypican 3 (GPC3) gene meth-
ylation has also been implicated in mesothelioma.12
Allelic loss at GPC3, whose human homolog is mutated
in the Simpson-Golabi-Behmel overgrowth syndrome,
was infrequent (6.9%) in MM cell lines, and no mutations
were found. However, in majority of MM tumors and
MM cell lines, GPC3 transcript levels were markedly
decreased, and the GPC3 promoter region was shown to
have aberrant methylation.12 Similarly, methylation of
RARb2 and CCND2 (CyclinD2) gene has been associated
with various types of cancers from breast, stomach, lung,
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to head and neck.1,2,13–16 Clinical feasibility of methyla-
tion-specific PCR using cytology samples such as breast
FNA biopsies and ductal-lavage specimens has been dem-
onstrated.1,17 Real-time MSP, which offers faster turn
around time than conventional MSP and also has potential
for semi-quantitative analysis, has been used in clinical
research.16,18
In this article, we present results of a pilot study in
which we investigate the use of methylation profiles of a
panel of genes including RARb2, GPC3, CDKN2A, TERT,
and CCND2 derived from real-time MSP to distinguish




Sixty-three cases were retrieved from the AFIP and Uni-
versity of Michigan archives with IRB approval. Those
cases had either unstained slides or paraffin blocks pre-
pared from biopsy or effusion available. Forty-one cases
were MM, diagnosed by unequivocal morphological fea-
tures and most also confirmed by immunohistochemical
studies and clinical follow up information, while 22 cases
were RM with different underlying diseases. Unstained
slides were soaked with extraction buffer and scraped into
Eppendorf tubes for DNA extraction.1 Sections from par-
affin blocks were cut at 4-lm thickness for Hemotoxylin/
Eosin staining and morphologic examination, and 4–6
sections of 10-lm thickness sections were collected into
an Eppendorf tube for genomic DNA extraction following
previous established protocol.1,19 Purified genomic DNA
was treated with sodium bisulfite according to established
protocols1,19 and analyzed using a real-time MSP assay.
Real-Time Methylation-Specific PCR
Sodium bisulfite-treated genomic DNA was amplified
using fluorescence-based real-time methylation-specific
PCR. Methylation of CDKN2A, RARb2, CCND2, TERT,
and GPC3 genes was examined using b-Actin and/or Her-
2 as the internal control for DNA quantification. Control
of sodium bisulfite treatment was also ensured by includ-
ing genomic DNA from the MDA-MB-231 cell line that
generates positive result for RARb2 amplification reaction,
since RARb2 is known to be methylated in this cell line.1
Briefly, sodium bisulfite-converted genomic DNA was
amplified with locus-specific PCR primers and dual la-
beled fluorogenic probes. During the extension phase of
PCR, the 50 to 30 nuclease activity of Taq-polymerase
cleaves the probe and releases the reporter, whose fluores-
cence can be detected by the laser detector of the ABI
Prism 7700 Sequence Detection System. After crossing a
fluorescence detection threshold, the PCR amplification
results in a fluorescent signal proportional to the amount
of PCR product generated. Primers and probes, specifi-
cally for sodium bisulfite-converted DNA sequences for
CDKN2A, RARb2, and CCND2 genes, were based on
published data.16 For HERT and GPC3, the primers and
probes were designed based on sequence analysis. All
primer and probe sequences are listed in Table I. For
DNA quantity control, Her-2 primers and probes were
used. Another control used was selected from a region of
b-Actin that contains no CpG di-nucleotides thus not
affected by DNA methylation status and sodium bisulfite-
treatment (Table I). Real-time PCR was set up in a total
volume of 50 ll containing 1X Taqman universal PCR
master mix, 400 nM of each primer, 100 nM of probe and
up to 2 ll sodium bisulfite treated-DNA samples. After
an initial denature step at 508C for 2 min and 958C for 10
min, 45 or 50 cycles of 15 sec at 958C and 1 min at 608C
were followed. Amplification data, collected by the 7700
sequence detector was analyzed using software developed
by PE Applied Biosystems (Foster City, CA). Samples
with reactions that show exponential increase of signal
over cycle numbers were considered positive while reac-
tions had no such increase was considered negative (Fig. 1).
Statistical Analysis
This was performed using Fisher Exact test; a two-sided
P value of less than 0.05 was considered significant.
Table I. List of Primers and Probes for the Real-Time MSP Assay
Actin
Forward TGG TGA TGG AGG AGG TTT AGT AAG T
Reverse AAC CAA TAA AAC CTA CTC CTC CCT TAA
Probe FAM-ACC ACC ACC CAA CAC ACA ATA
ACA AAC ACA-TAMRA
RARb2
Forward TTT GAG GAT TGG GAT GTC GAG
Reverse CGA ATC CTA CCC CGA CGA TA
Probe FAM-CGC GAG CGA TTC GAG TAG GGT
TTG TTT-TAMRA
Her-2
Forward ATG CAG ATT GCC AAG GTA TGC
Reverse GGA AGC ACC CAT GTA GAC CTT CT
Probe Vic-CCG GAG CAA ACC CCT ATG TCC
ACA A-TARMA
CDKN2A(P16)
Forward GGG GAG AGT AGA TAG CGG GGC
Reverse AAC CAA TCA ACC GAA AAT TCC ATA
Probe FAM-TAC TCC CCG CCG CCG ACT
CCA T-TAMRA
GPC3
Forward GGT CGG GAT CGT GCG TAT
Reverse CCT ATC CCG AAA AAT CCA AAC TAA
Probe FAM-CGT GTT TGG TGG TGG CGA
TGT TG-TAMRA
TERT
Forward AAG CGC GGT TTA GAT TTT CG
Reverse GAA TCC ACT AAA AAC CCG ACC TAA C
Probe FAM-TTC GTT CGG AGT AGT TGC GTT
GTC GG-TAMRA
CCND2
Forward TTT GAT TTAAGG ATG CGT TAG AGT ACG
Reverse ACT TTC TCC CTA AAA ACC GAC TAC G
Probe FAM-AAT CCG CCA ACA CGA TCG ACC
CTA-TAMRA
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Results
Of the 63 cases, 42 (67%) yielded informative results
(generated PCR products on either the b-Actin and/or
Her-2 amplification reaction, Fig. 1). Of these 42 cases,
27 were MM cases and 15 were from cases with diagno-
sis of RM. MM cases consisted of mostly the epithelial
type (25 cases) with two cases of the sarcomatoid type.
The demographic information was available from only
12 MM patients with similar gender distribution (7 male and
5 female) and a mean age of 63.2 yr and from 13 RM
patients who were mostly female and slightly younger (11
female and 2 male, mean age: 47.0, Table II). In the MM
group, 17 of the 27 cases demonstrated methylation of at
least one of the genes tested (Fig. 2). Eight of them had
two or more genes methylated. In contrast, in the RM
group, methylation was found in only 5 of 15 cases, sig-
nificantly lower than the MM group (P < 0.05, Fig. 2).
Individually, the frequency of RARb2 gene methylation
was higher in the MM cases than in the RM cases,
although the difference was not statistically significant
(15 of 27 cases vs. 4 of 15 cases, P > 0.05, Fig. 2).
GPC3 gene methylation frequency was also found to be
higher in the MM group than the RM group (9 of 25
cases vs. 4 of 15 cases, P > 0.05, Fig. 2). Methylation of
Fig. 1. Example of real time-PCR of the b-Actin gene amplification plot
of one set of reactions. Each color represents one sample. On the graph
of reaction (DRn) vs. Cycle number, the threshold cycle occurs where
the sequence detection application begins to detect the increase in signal
associated with exponential growth of PCR product (positive specimens).
At any given cycle within the exponential phase of PCR, the amount of
product is proportional to the initial number of template copies. With
negative specimens, product lines do not show exponential increase or
cross over the threshold. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
Table II. Demographic Data of the 25 Patients in the Cohort Show
Similar Age Between Methylation Positive (þ Methyl) and Negative
( Methyl) Cases in MM or RM Groups
Diagnosis
Gender Age (mean, yr)
Male Female All cases þ Methyl  Methyl
MM 7 5 63.2 63.4 62.8
RM 2 11 47.0 45.3 48.4
Fig. 2. Gene methylation is more frequently observed in MM than RM
cases. Solid-black block indicates methylation while empty block indi-
cates no methylation observed and ‘‘/’’ indicates not performed.
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TERT and CDKN2A was each found in one case of the
MM group (4%), respectively, but none of the RM group.
CCND2 methylation was not detected in any of the cases
examined (Fig. 2). RASSF1A was not methylated in any
cases, although few cases were examined (data not
shown).
There was no significant age difference of the patients
with respect to their methylation status among the MM
and RM groups (Table II). Although the MM group
patient were older (mean age: 63.2) than the RM group,
within each group the methylation positive or negative
patients have similar age. In MM patient group, methyla-
tion positive patients had an average age of 63.4 while
methylation negative patients with an average age of
62.8. In RM group, methylation positive patients had an
average age of 45.3 while methylation negative patients
with an average age of 48.4.
Discussion
We were able to use real-time MSP to acquire methyla-
tion profiles of MM and RM from archival paraffin sec-
tions in surgical biopsy and cytology effusion specimens.
Real-time PCR offers rapid turnaround time and has the
potential for semi-quantitative analysis. The rate of in-
formative results (*67%) was similar to the conventional
MSP method (R. Pu, data not shown) and the real-time
MSP results from other investigators (vide infra). For
example, one study showed 29 of 45 paraffin block speci-
mens were informative for real-time PCR amplification.20
The inability to obtain methylation profiles in 1/3 of the
cases was most likely due to less than optimal DNA qual-
ity and low quantitative yields of DNA from the archival
material. The informative rate can be enhanced by using
fresh material if real-time MSP proved to be useful ancil-
lary tool by more comprehensive studies in the future.
Although our study did not show significant differences in
individual gene methylation frequency, the overall meth-
ylation in MM was significantly higher than that of RM
(63% vs. 33%, P < 0.05). In our study, MM patients
were older than the RM patients, a potential problem in
interpretation of the result since some DNA methylation
events have been shown to be age-related phenom-
ena.11,21,22 However, in both MM and RM groups, the
patient age was similar in methylation positive and nega-
tive patients, arguing against the possibility that aging
contributes to the higher observed methylation percentage
in MM group.
It is known that certain tumor suppressor gene methyla-
tion events may occur earlier than the other genes during
tumorigenesis. RARb2 is noted to have moderate levels of
methylation in benign and pre-cancer lesions, e.g. fibroa-
denoma and papilloma in breast.1 We found methylation
of RARb2 in 56% of MM cases, highest among all the
genes examined, but also in 33% of RM cases. Our result
suggests that methylation of RARb2 may occur in benign
condition and, if involved in MM development, likely an
early event, similar to its role in other types of neopla-
sia.1,13 Similarly, GPC3 gene methylation may be an
early event during MM development as we found moder-
ate level of methylation in MM (36%) as well as RM
(27%) cases. Although alterations of CDKN2A are very
common in MM, we found methylation of CDKN2A in
only a small percentage of MM cases (4%), similar to
8.8% reported by others.3 This suggests that methylation
of CDKN2A does not play a major role in its down regula-
tion in MM, in contrast to a high prevalence of CDKN2A
methylation in other type of cancers, such as squamous
cell carcinoma of the lung (90%).13
Methylation of TERT promoter, resulting in activating
telomerase activity, was considered idiosyncratic in com-
parison to the usual function of methylation in down-reg-
ulation of gene expression.6 Whether any of the CpG di-
nucleotides in the TERT promoter region is important for
its function in MM has not been analyzed in detail,
although most of the promoter region has been shown to
be methylated in other types of TERT-positive tumors and
cell lines.7 We found only one case of MM having DNA
methylation in the promoter region that we interrogated
while none in the benign cases. The sequences of our pri-
mers and probe correspond to the DNA sequence from
273 to 346 relative to ATG translation start site and
contain 9 CpG di-nucleotides. Although TERT methyla-
tion was less common than we anticipated, it is possible
that in MM, those 9 CpGs are not as frequently methyl-
ated as in other TERT positive tumors or cell lines studied
by sequencing analysis.7 Similarly, CCND2 methylation
was not found in any MM/RM cases examined. The
CCND2 sequences examined in this case, however, have
been shown to be methylated in other malignancies.1,16
This suggests that in MM tumorigenesis, CCND2 methyl-
ation may not play as an important role as it does in other
carcinomas.1,16
In summary, we found DNA methylation is more fre-
quent in MM (epithelial type) than RM in most of the
genes examined, although no individual gene showed stat-
istically significant differences in methylation. The poten-
tial clinical utility of methylation profiling using real-time
MSP to differentiate MM from RM and from other malig-
nancy is supported by our results and other publication.23
Increasing the number of samples and genes examined,
and utilizing freshly obtained specimens may provide a
more complete evaluation of whether methylation profil-
ing can be used as an ancillary tool in differentiating mes-
othelioma from benign mesothelial proliferation.
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